244 related articles for article (PubMed ID: 26434663)
1. Cytogenetic and oxidative status of human lymphocytes after exposure to clinically relevant concentrations of antimalarial drugs atovaquone and proguanil hydrochloride in vitro.
Dinter D; Gajski G; Domijan AM; Garaj-Vrhovac V
Fundam Clin Pharmacol; 2015 Dec; 29(6):575-85. PubMed ID: 26434663
[TBL] [Abstract][Full Text] [Related]
2. Atovaquone and proguanil hydrochloride for prophylaxis of malaria.
Shanks GD; Kremsner PG; Sukwa TY; van der Berg JD; Shapiro TA; Scott TR; Chulay JD;
J Travel Med; 1999 May; 6 Suppl 1():S21-7. PubMed ID: 23573549
[TBL] [Abstract][Full Text] [Related]
3. Atovaquone and proguanil hydrochloride for treatment of malaria.
Kremsner PG; Looareesuwan S; Chulay JD
J Travel Med; 1999 May; 6 Suppl 1():S18-20. PubMed ID: 23573548
[TBL] [Abstract][Full Text] [Related]
4. Atovaquone and proguanil hydrochloride: a review of nonclinical studies.
Pudney M; Gutteridge W; Zeman A; Dickins M; Woolley JL
J Travel Med; 1999 May; 6 Suppl 1():S8-12. PubMed ID: 23573546
[TBL] [Abstract][Full Text] [Related]
5. [Atovaquone-proguanil treatment failure in Plasmodium falciparum].
Contentin L; Grammatico-Guillon L; Desoubeaux G; Baron S; Thanh HD
Presse Med; 2011 Nov; 40(11):1081-3. PubMed ID: 21570798
[No Abstract] [Full Text] [Related]
6. Clinical pharmacology of atovaquone and proguanil hydrochloride.
Beerahee M
J Travel Med; 1999 May; 6 Suppl 1():S13-7. PubMed ID: 23573547
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women.
Na-Bangchang K; Manyando C; Ruengweerayut R; Kioy D; Mulenga M; Miller GB; Konsil J
Eur J Clin Pharmacol; 2005 Sep; 61(8):573-82. PubMed ID: 16041597
[TBL] [Abstract][Full Text] [Related]
8. Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria.
McKeage K; Scott L
Drugs; 2003; 63(6):597-623. PubMed ID: 12656656
[TBL] [Abstract][Full Text] [Related]
9. Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil.
Sutherland CJ; Laundy M; Price N; Burke M; Fivelman QL; Pasvol G; Klein JL; Chiodini PL
Malar J; 2008 Nov; 7():240. PubMed ID: 19021900
[TBL] [Abstract][Full Text] [Related]
10. Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II).
Boggild AK; Parise ME; Lewis LS; Kain KC
Am J Trop Med Hyg; 2007 Feb; 76(2):208-23. PubMed ID: 17297027
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Analysis of the Interaction between Atovaquone and Proguanil against Liver Stage Malaria Parasites.
Barata L; Houzé P; Boutbibe K; Zanghi G; Franetich JF; Mazier D; Clain J
Antimicrob Agents Chemother; 2016 Jul; 60(7):4333-5. PubMed ID: 26926628
[TBL] [Abstract][Full Text] [Related]
12. An alkaline comet assay study on the antimalarial drug atovaquone in human peripheral blood lymphocytes: a study based on clinically relevant concentrations.
Dinter D; Gajski G; Garaj-Vrhovac V
J Appl Toxicol; 2013 Jan; 33(1):56-62. PubMed ID: 21735454
[TBL] [Abstract][Full Text] [Related]
13. Proguanil polymorphism does not affect the antimalarial activity of proguanil combined with atovaquone in vitro.
Edstein MD; Yeo AE; Kyle DE; Looareesuwan S; Wilairatana P; Rieckmann KH
Trans R Soc Trop Med Hyg; 1996; 90(4):418-21. PubMed ID: 8882194
[TBL] [Abstract][Full Text] [Related]
14. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group.
Looareesuwan S; Chulay JD; Canfield CJ; Hutchinson DB
Am J Trop Med Hyg; 1999 Apr; 60(4):533-41. PubMed ID: 10348225
[TBL] [Abstract][Full Text] [Related]
15. Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model.
Deye GA; Miller RS; Miller L; Salas CJ; Tosh D; Macareo L; Smith BL; Fracisco S; Clemens EG; Murphy J; Sousa JC; Dumler JS; Magill AJ
Clin Infect Dis; 2012 Jan; 54(2):232-9. PubMed ID: 22052893
[TBL] [Abstract][Full Text] [Related]
16. [Fluindione and falciparum malaria treated by atovaquone-proguanil].
Kamaliddin C; Joste V; Argy N; Houzé S
Therapie; 2018 Oct; 73(5):445-447. PubMed ID: 29680373
[No Abstract] [Full Text] [Related]
17. Atovaquone + proguanil: new preparation. Second-line antimalarial combination.
Prescrire Int; 2002 Oct; 11(61):131-6. PubMed ID: 12378742
[TBL] [Abstract][Full Text] [Related]
18. Late clinical failure associated with cytochrome b codon 268 mutation during treatment of falciparum malaria with atovaquone-proguanil in traveller returning from Congo.
Massamba L; Madamet M; Benoit N; Chevalier A; Fonta I; Mondain V; Jeandel PY; Amalvict R; Delaunay P; Mosnier J; Marty P; Pomares C; Pradines B
Malar J; 2020 Jan; 19(1):37. PubMed ID: 31964401
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of atovaquone-proguanil compared with mefloquine in the treatment of nonimmune patients with uncomplicated P. falciparum malaria in Japan.
Hitani A; Nakamura T; Ohtomo H; Nawa Y; Kimura M
J Infect Chemother; 2006 Oct; 12(5):277-82. PubMed ID: 17109092
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria.
Sabchareon A; Attanath P; Phanuaksook P; Chanthavanich P; Poonpanich Y; Mookmanee D; Chongsuphajaisiddhi T; Sadler BM; Hussein Z; Canfield CJ; Hutchinson DB
Trans R Soc Trop Med Hyg; 1998; 92(2):201-6. PubMed ID: 9764334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
